Alpine Immune Sciences

Alpine Immune Sciences Net Margin

Delisted

The Net Profit Margin of Alpine Immune Sciences (ALPN) as of Nov 17, 2026 is -54.66 %. In the previous year, Net Profit Margin was -192.13 % — a change of -71.55% (higher).

Net Margin

-54.66 %

YoY

-71.55%

Last updated:

Net Profit Margin of Alpine Immune Sciences is 2023 -54.66 % . Net Profit Margin of Alpine Immune Sciences was 2022 -192.13 % . It decreases by -71.55% higher compared to the previous year.

For Alpine Immune Sciences, the net margin of -54.7% is up versus -2,444.5% a few years ago.

The Alpine Immune Sciences Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2016
-1,066.54 USD
Jan 1, 2017
-449.62 USD
Jan 1, 2018
-5,175.46 USD
Jan 1, 2019
-2,444.48 USD
Jan 1, 2020
-299.30 USD
Jan 1, 2021
-214.70 USD
Jan 1, 2022
-192.13 USD
Jan 1, 2023
-54.66 USD
The Alpine Immune Sciences Net Margin history
YEARNet MarginYoY
-54.66 %-71.55%
-192.13 %-10.51%
-214.70 %-28.27%
-299.30 %-87.76%
-2,444.48 %-52.77%
-5,175.46 %+1,051.06%
-449.62 %-57.84%
-1,066.54 %-77.00%
-4,637.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alpine Immune Sciences Stock analysis

What does Alpine Immune Sciences do? Alpine Immune Sciences Inc. is a biopharmaceutical company specializing in the research and development of immunotherapies. Founded in 2015, the company is based in Seattle, Washington and holds numerous patents in the field of immunology. Alpine's business model is to utilize clinical science and innovative technologies to revolutionize immunotherapy. The company combines antibodies and other immunological agents to significantly improve the effectiveness and safety of therapies. The company is divided into several divisions, each offering different products and services. One division focuses on the discovery of novel antibodies and other biological agents. Through various technology platforms, Alpine continuously develops groundbreaking therapies that have the potential to revolutionize the treatment of cancer, autoimmune diseases, and other illnesses. Another division of Alpine is dedicated to the field of immuno-oncology, specifically researching and developing immunotherapies against cancer. The main goal is to enhance the body's own immune defenses against cancer cells. Furthermore, Alpine also develops therapies for specific autoimmune diseases, where the body's immune system attacks its own cells and tissues. In this area as well, the company relies on combining different immunological agents to increase the effectiveness and safety of the therapy. One of Alpine's most well-known products is ALPN-101, a novel antibody that can be used in immunotherapy against cancer and autoimmune diseases. This antibody has the potential to improve the effectiveness and safety of existing therapies, contributing to the cure and relief of illnesses. Alpine Immune Sciences Inc. has an impressive track record, having made significant progress in the field of immunotherapy in a short period of time and establishing itself as a leading provider of innovative therapies. Additionally, Alpine has successfully formed partnerships with other companies and institutions to advance its research and development. Overall, Alpine Immune Sciences Inc. represents a forward-thinking and innovative approach to immunotherapy, with the potential to change the lives of millions of people worldwide. Alpine Immune Sciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alpine Immune Sciences stock

Net Profit Margin of Alpine Immune Sciences is -54.66 % in 2023.

Net Profit Margin of Alpine Immune Sciences changed from -192.13 % to -54.66 %, representing a -71.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Alpine Immune Sciences since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Alpine Immune Sciences with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Alpine Immune Sciences

All Key Metrics — Alpine Immune Sciences